AstraZeneca's selumetinib stumbles in Phase III
This article was originally published in Scrip
Executive Summary
One of AstraZeneca's key prospects in oncology, selumetinib, has failed in at the Phase III stage in one of its potential indications, uveal melanoma.
You may also be interested in...
Fresh Win For AstraZeneca/Merck & Co Pact With Koselugo Approval
Koselugo (selumetinib) was largely forgotten after failing Phase III trials in thyroid and lung cancer, as well as uveal melanoma, but its approval in Europe for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1, which follows a US approval for the rare condition last year, has breathed new life into the once-lauded MEK 1/2 inhibitor.
Keeping Track: Industry Channels Inner Gottlieb As Commissioner Departs US FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
Another Late-Stage Failure For AstraZeneca's Selumetinib
AstraZeneca's novel targeted anticancer selumetinib has missed its endpoints in a Phase III study in lung cancer, the second late-stage failure for the product, which last year disappointed in uveal melanoma.